Search

everythinglearnresearchcommunity

for

Search:↓

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.

Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Proper management of skin and hair side effects from chemotherapy improves patients' quality of life.

More research is needed to understand chemotherapy-induced hair loss and its phases.

The compound 4c showed strong potential as an anticancer agent.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.

Intravenous arsenic is safe and effective for treating certain blood cancers.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Most patients experienced significant but reversible hair loss during treatment.

Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.

Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Targeted cancer therapies can cause new side effects, requiring careful monitoring and management to ensure patient safety.

New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.